PRIMAL THERAPIES, INC.

BOISE, ID · Founded 2012 · CIK 0001688401 · Biotech · Private

PTx800, a GRAS ingredient combination that selectively inhibits pathogenic oral bacteria metabolism while preserving health-promoting bacteria

primaltherapies.com →
Grants
$206K
1 award
Sector median: 1
Raised
$677K
1 Form D · Oct 2016
120 months since last filing
Contracts
—
No federal contracts on record
Patents
5
2 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$677,022
Federal grantDepartment of Health and Human Services · Phase I · Evaluation of a daily oral care lozenge on oral health and quality of life in older adults$206,479
Federal grant · SBIR/STTRForm D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
1177Dnalite Therapeutics, Inc.—$5.6M
1178Xenon Pharmaceuticals——
1179Pagari Life Science Corp.—$678K
1180PRIMAL THERAPIES, INC.—$677K
1181Grace Bio-Labs, Inc.——
1182NEUREXIS THERAPEUTICS, INC.—$605K
1183IQuity Labs, Inc.—$600K

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 4 related persons
  • David EigenDirector
  • Terry FademDirector
  • Michael O'DonnellExecutive Officer
  • Emily SteinDirector · Executive Officer

Patents

USPTO · 2 granted of 5

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.